We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Teva Pharmaceutical Industries Ltd | NYSE:TEVA | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 14.08 | 14.16 | 13.96 | 14.15 | 7,051,252 | 01:00:00 |
From May 2019 to May 2024
By Cecilia Butini
The European Commission said Thursday that it has opened a formal antitrust investigation into Israel-based pharmaceutical company Teva Pharmaceutical Industries Ltd. to assess whether it behaved in an anti-competitive manner with regards to its multiple-sclerosis drug Copaxone.
The investigation aims to determine whether Teva illegally delayed the market entry and uptake of medicines that compete with its own, the Commission said.
It will also examine whether the company has put together a communication campaign with the goal of hindering the use of competing products with the same active principle, it said.
Teva's alleged behavior may amount to an abuse of dominant position if proven, the Commission said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
March 04, 2021 06:04 ET (11:04 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Teva Pharmaceutical Indu... Chart |
1 Month Teva Pharmaceutical Indu... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
